To validate the NGS platform we first analyzed seven independent tumor FFPE samples from lung, colon and melanoma with known mutations in BRAF (V600E), KRAS (G12S, G13D), and EGFR (L858R and E746_A750del). This evidence concerns the gene KRAS and melanoma.